⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27889907 | 0.98 | CYP2D6 (0.47) | — | |
| SCHEMBL7059821 | 0.98 | CYP2D6 (0.52) | — | |
| SCHEMBL1479655 | 0.93 | — | — | |
| SCHEMBL7155220 | 0.93 | — | — | |
| SCHEMBL7158350 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL19285633 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL19285411 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL19285410 | 0.91 | — | — | |
| SCHEMBL16767662 | 0.82 | POLB (0.40) | — | |
| SCHEMBL10809053 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421887-B1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES AS (DK) | 2015-04-22 | — | — | EP | claimed |
| CN-102428097-B | Method For The Manufacture Of Degarelix | POLYPEPTIDE LABORATORIES A/S (DK) | 2014-10-29 | — | — | CN | claimed |
| US-8828938-B2 | Method for the manufacture of degarelix | POLYPEPTIDE LABORATORIES A/S (DK) | 2014-09-09 | — | — | US | claimed |
| CN-102428097-A | Method for producing degarelix | POLYPEPTIDE LABORATORIES AS (DK) | 2012-04-25 | — | — | CN | claimed |
| EP-2421887-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | Polypeptide Laboratories A/S (DK) | 2012-02-29 | — | — | EP | claimed |
| US-20120041172-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2012-02-16 | — | — | US | claimed |
| WO-2010121835-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2010-10-28 | — | — | WO | claimed |
| EP-1351955-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053561-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-07-11 | — | — | WO | claimed |
| US-12037338-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-07-16 | — | — | US | disclosed |
| EP-3842436-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | SK BIOPHARMACEUTICALS CO LTD (KR) | 2023-11-08 | — | — | EP | disclosed |
| US-20210300933-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-09-30 | — | — | US | disclosed |
| EP-3842436-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | SK Biopharmaceuticals Co., Ltd. (KR) | 2021-06-30 | — | — | EP | disclosed |
| US-11046702-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-06-29 | — | — | US | disclosed |
| EP-1098864-B1 | METHOD FOR HYDROGENATING UNSATURATED HETEROCYCLIC COMPOUNDS | BASF AG (DE) | 2004-10-06 | — | — | EP | disclosed |
| US-6583286-B1 | High yield catalytic conversion of pyridine and/or alkyl-pyridines to the corresponding piperidines | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-24 | — | — | US | disclosed |
| EP-1098864-A1 | METHOD FOR HYDROGENATING UNSATURATED HETEROCYCLIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000005184-A1 | METHOD FOR HYDROGENATING UNSATURATED HETEROCYCLIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-03 | — | — | WO | disclosed |
| EP-0201275-B1 | Pharmaceutical compositions for treating metastasis of cancerous tumors | ALPHA THERAPEUTIC CORP (US) | 1993-12-08 | — | — | EP | disclosed |
| US-4725628-A | Process of making a crosslinked superabsorbent polyurethane foam | KIMBERLY-CLARK CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |